Join
Live feed
·
PRReleasevia Quantisnow
Verastem Inc. logo

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

ByQuantisnow·Wall Street's wire, on your screen.
VSTM· Verastem Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VSTM (Verastem Inc.) and more on Quantisnow.